YMAB

Q: What is the price of Y-mAbs Therapeutics (YMAB) today?

The price of Y-mAbs Therapeutics (YMAB) today is $ 0.00, with return of 0% compared to the last year. The price of Y-mAbs Therapeutics (YMAB) started the year trading around $ 0.00 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Y-mAbs Therapeutics (YMAB) and international markets.

Q: When does Y-mAbs Therapeutics (YMAB) pay dividends?

Y-mAbs Therapeutics (YMAB) did not distribute dividends in the last year.

Q: Is Y-mAbs Therapeutics (YMAB) worth it?

Currently, Y-mAbs Therapeutics (YMAB) is priced at $ 0.00, with a P/E of -20.98%, representing a deviation of -1,099% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Y-mAbs Therapeutics (YMAB) stock?

Investing in stocks of Y-mAbs Therapeutics (YMAB) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Y-mAbs Therapeutics (YMAB) yield today?

The yield of Y-mAbs Therapeutics (YMAB) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Y-mAbs Therapeutics (YMAB) today, the total investment would be $ 0.00, based on the current price of $ 0.00.If past performance were to repeat, the return on your investment would be:In 1 year: $ 0.00In 5 years: $ 0.00In 10 years: $ 0.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Y-mAbs Therapeutics Inc.

Price

$ -

return (12m)

0.00%

p/e

-20.98

p/bv

4.43

DIVIDEND YIELD

0.00%

YMAB price

YMAB

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment YMAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals YMAB

review the fundamentals of Y-mAbs Therapeutics shares

P/E

-20.98

Sector: -3.75 Industry: -3.75

P/S (PSR)

4.48

Sector: -4.18 Industry: -4.18

P/BV

4.43

Sector: 1.79 Industry: 1.79

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-15.76%

Sector: -62.10% Industry: -62.10%

ROE

-21.11%

Sector: -62.98% Industry: -62.98%

ROIC

-61.43%

Sector: -1,220.49% Industry: -1,220.49%

NET MARGIN

-21.37%

Sector: -39.10% Industry: -39.10%

GROSS MARGIN

81.29%

Sector: 38.12% Industry: 38.12%

OPERATING MARGIN

-27.39%

Sector: -39.31% Industry: -39.31%

EV/EBITDA

-16.56

Sector: -3.57 Industry: -3.57

EV/EBIT

-16.36

Sector: -3.78 Industry: -3.78

PRICE-TO-ASSETS

3.31

Sector: 1.30 Industry: 1.30

BVPS

1.94

Sector: 1.88 Industry: 1.88

EPS

-0.41

Sector: -2.04 Industry: -2.04

EQUITY-TO-ASSETS RATIO

0.75

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.25

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

17.57%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-30.94%

Sector: - Industry: -

Fundamentals YMAB

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.61	7.31	33.81%	2.16%	$ 579.24 B	28.46%
PFE	19.79	1.65	8.35%	6.36%	$ 153.75 B	12.42%
ABBV	87.56	0.00	0.00%	3.18%	$ 370.01 B	6.91%
NVO	10.22	5.26	51.50%	4.68%	$ 160.05 B	33.05%
MRK	16.27	0.00	0.00%	2.74%	$ 296.92 B	28.08%
AZN	28.58	6.00	20.99%	1.70%	$ 292.24 B	17.41%
GILD	19.48	7.33	37.62%	2.39%	$ 165.80 B	28.90%
BMY	16.90	-3.50	-20.72%	4.25%	$ 119.19 B	14.64%
ZTS	18.57	14.90	80.25%	1.79%	$ 49.65 B	28.23%
REGN	16.87	2.43	14.41%	0.49%	$ 75.98 B	31.41%
HALO	22.95	148.99	649.21%	0.00%	$ 7.27 B	22.69%
AMGN	24.38	21.71	89.06%	2.77%	$ 187.99 B	20.98%
MCK	24.38	-1,068.68	-4,383.84%	0.36%	$ 105.80 B	1.09%
VRTX	27.83	5.89	21.18%	0.00%	$ 110.00 B	32.94%
CAH	29.33	-18.06	-61.56%	0.99%	$ 48.75 B	0.68%
ADMA	14.98	4.61	30.78%	0.00%	$ 2.20 B	28.80%
BIIB	20.90	1.48	7.08%	0.00%	$ 27.02 B	13.07%
HRMY	9.53	1.74	18.24%	0.00%	$ 1.51 B	18.27%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

YMAB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2018

Time since IPO - 8 years

125

Employees

The Company Y-mAbs Therapeutics Inc. (United States), is listed on Nasdaq with a market value of $ 387.45 Millions, having an equity of $ 87.49 Millions.

With a total of 125 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 86.44 Millions, which generated a loss in the amount of $ -18.47 Millions.

As for its main indicators, the Company has a P/E ratio of -20.98, a P/BV ratio of 4.43 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker YMAB.

Market cap

$ 387.45 Millions

Net worth

$ 87.49 Millions

US$ 87,490,000.00

Assets

$ 117.21 Millions

US$ 117,210,000.00

Total Shares Outstanding

45.00 Millions

45,000,000

Average Daily Trading Volume

$ 1.07 Million

US$ 1,065,291.50

Sector

Health Care

Industry

Biotechnology

YMAB

YMAB revenue and profits

Financial Results YMAB

DRAG THE FRAME TO SEE MORE DATA

YMAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 884.28 23,83% (12M)

P/E

24.38

0.36%

ROE

-4,383.84%

P/BV

-1,068.68

CAH - Cardinal Health

$ 214.05 58,49% (12M)

P/E

29.33

0.99%

ROE

-61.56%

P/BV

-18.06

JNJ - Johnson & Johnson

$ 243.04 56,31% (12M)

P/E

21.61

2.16%

ROE

33.81%

P/BV

7.31

PFE - Pfizer

$ 28.32 25,05% (12M)

P/E

19.79

6.36%

ROE

8.35%

P/BV

1.65

ABBV - AbbVie

$ 208.84 7,85% (12M)

P/E

87.56

3.18%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 120.87 46,25% (12M)

P/E

16.27

2.74%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 203.49 51,28% (12M)

P/E

28.58

1.70%

ROE

20.99%

P/BV

6.00

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 884.28 23,83% (12 M)

P/L

24.38

0.36%

ROE

-4,383.84%

P/VP

-1,068.68

CAH - Cardinal Health

$ 214.05 58,49% (12 M)

P/L

29.33

0.99%

ROE

-61.56%

P/VP

-18.06

JNJ - Johnson & Johnson

$ 243.04 56,31% (12 M)

P/L

21.61

2.16%

ROE

33.81%

P/VP

7.31

PFE - Pfizer

$ 28.32 25,05% (12 M)

P/L

19.79

6.36%

ROE

8.35%

P/VP

1.65

ABBV - AbbVie

$ 208.84 7,85% (12 M)

P/L

87.56

3.18%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 120.87 46,25% (12 M)

P/L

16.27

2.74%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 203.49 51,28% (12 M)

P/L

28.58

1.70%

ROE

20.99%

P/VP

6.00

Frequently Asked Questions

What is the price of Y-mAbs Therapeutics (YMAB) today?

The price of Y-mAbs Therapeutics (YMAB) today is $ 0.00, with return of 0% compared to the last year. The price of Y-mAbs Therapeutics (YMAB) started the year trading around $ 0.00 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Y-mAbs Therapeutics (YMAB) and international markets.

When does Y-mAbs Therapeutics (YMAB) pay dividends?

Y-mAbs Therapeutics (YMAB) did not distribute dividends in the last year.

Is Y-mAbs Therapeutics (YMAB) worth it?

Currently, Y-mAbs Therapeutics (YMAB) is priced at $ 0.00, with a P/E of -20.98%, representing a deviation of -1,099% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Y-mAbs Therapeutics (YMAB) stock?

Investing in stocks of Y-mAbs Therapeutics (YMAB) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Y-mAbs Therapeutics (YMAB) yield today?

The yield of Y-mAbs Therapeutics (YMAB) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Y-mAbs Therapeutics (YMAB) today, the total investment would be $ 0.00, based on the current price of $ 0.00.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 0.00
In 5 years: $ 0.00
In 10 years: $ 0.00

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

YMAB

Y-mAbs Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment YMAB

review the fundamentals of Y-mAbs Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

United States

11 years

2018

125

PROFIT X PRICE YMAB

Financial Results YMAB

YMAB cash flow

Asset, Revenue and Profit Growth - YMAB

YMAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions